A 43-year-old man presents to his endocrinologist with a 3-year history of progressively enlarging hands and feet, coarsening of facial features, and excessive sweating that soaks through his clothing daily. He also reports fatigue, joint pain, and was recently diagnosed with glucose intolerance on routine bloodwork. His blood pressure is 148/92 mmHg, heart rate is 78/min, and BMI is 29 kg/m². Physical examination reveals prognathism, macroglossia, widely spaced teeth, and a prominent supraorbital ridge. Serum IGF-1 level is markedly elevated at 680 ng/mL (normal: 115–307 ng/mL), and an oral glucose tolerance test fails to suppress growth hormone below 1 ng/mL. MRI of the brain demonstrates a pituitary macroadenoma measuring 1.4 cm with suprasellar extension; surgical resection is deferred due to the patient's comorbidities. He is started on a long-acting somatostatin analog that suppresses growth hormone release and is also used in the management of carcinoid syndrome and esophageal variceal bleeding. Which of the following drugs was most likely prescribed?

1. A)OctreotideGABARITO
2. B)Leuprolide
3. C)Desmopressin
4. D)Pegvisomant
5. E)Cabergoline